Table 3 Characteristics of PSC patients and controls
Controls (n = 48) | PSC (all) (n = 47) | p-valuea | PSC (early) (n = 24) | PSC (late) (n = 23) | p-valueb | |
|---|---|---|---|---|---|---|
Sex, % male | 58.3 | 59.6 | > 0.9999 | 62.5 | 56.5 | 0.4158 |
Race, %Caucasian | 100 | 98.0 | 0.4947 | 95.8 | 100 | 0.6085 |
Age at sample collection (yrs), median (IQR) | 52.3 (44.1–62.1) | 54.3 (32.8–62.1) | 0.4847 | 47.0 (29.8–58.7) | 57.4 (42.5–63.5) | 0.1599 |
ALP (xULN), median (IQR) | 0.59 (0.47–0.72) | 1.03 (0.86–3.65) | < 0.0001 | 0.86 (0.74–0.95) | 3.65 (2.96–5.36) | < 0.0001 |
Total bilirubin, median (IQR) | na | 0.8 (0.5–1.8) | – | 0.6 (0.5–0.9) | 1.6 (0.8–3.4) | < 0.0001 |
Age at Dx (yrs), median (IQR) | na | 42.4 (28.2–53.9) | – | 36.2 (22.0–48.5) | 46.1 (34.9–57.5) | 0.0693 |
IBD type | na | – | 0.3947 | |||
UC, n | 36 | 18 | 18 | |||
CD, n | 2 | 2 | 0 | |||
Ind. IBD, n | 3 | 2 | 1 | |||
None, n | 6 | 2 | 4 | |||
Disease duration (yrs), median (IQR) | na | 6.0 (3.0–12.0) | – | 5.0 (2.0–12.5) | 6.0 (3.0–12.0) | 0.8035 |
Clin. FU (yrs), median (IQR) | na | 5.0 (3.0–6.0) | – | 5.0 (4.0–6.8) | 4.0 (1.0–6.0) | 0.0699 |
UDCA treatment, (%) | na | 70.2 | – | 69.6 | 77.3 | 0.7381 |